Sublingual Product Articles & Analysis: Older
2 articles found
The global human insulin market is projected to surpass USD 40 Billion USD. Our sublingual “insulin+” product will be positioned in a particular segment of this market : it will be prescribed for type II diabetes patients, who do not respond sufficiently to GLP-1 analogues alone. Such a fixed dose combination is already on the market under the brand ...
Semaglutide is currently the only GLP-1 product available as an oral product. Biolingus aims at developing a sublingual version of this product. ...